Table 2 Suspected VAP episode description according to statin exposure and outcome
Overall | Statin previous users | Statin-naive patients | P | |
|---|---|---|---|---|
(n = 349) | (n = 93) | (n = 256) | ||
Time elapsed between ICU admission and VAP (days) | 10.0 (2.0-157.0) | 10.0 (2.0-72.0) | 10.0 (2.0-157.0) | 0.62 |
Time elapsed between MV onset and VAP (days) | 10.0 (2.0-156.0) | 10.0 (2.0-69.0) | 10.0 (2.0-156.0) | 0.48 |
Early VAP (n (%)) | 108 (30.9) | 27 (29.0) | 81 (31.6) | 0.64 |
Septic shock (n (%)) | 117 (33.6) | 35 (38.0) | 82 (32.0) | 0.29 |
Appropriate antibiotic therapy (n (%)) | 262 (76.4) | 70 (76.9) | 192 (76.2) | 0.89 |
Concurrent therapy during VAP period | ||||
Steroids (n (%)) | 153 (45.0) | 41 (45.1) | 112 (45.0) | 0.99 |
RRT (n (%)) | 83 (24.4) | 29 (31.9) | 54 (21.7) | 0.05 |
CPIS D1 | 6.0 (2.0-11.0) | 5.0 (2.0-9.0) | 6.0 (2.0-11.0) | 0.32 |
CPIS D3 | 7.0 (5.0-13.0) | 7.0 (5.0-11.0) | 7.0 (5.0-13.0) | 0.25 |
SOFA D1 | 8.0 (4.0-17.01) | 9.0 (4.0-16.0) | 8.0 (4.0-17.0) | 0.11 |
SOFA D3 | 8.0 (4.0-18.0) | 8.0 (4.0-15.0) | 8.0 (4.0-18.0) | 0.63 |
PCT D-1 | 1.2 (0.1-172.0) | 1.1 (0.1-55.9) | 1.4 (0.1-172.0) | 0.42 |
PCT D1 | 1.2 (0.1-91.4) | 1.3 (0.1-30.0) | 1.2 (0.1-91.4) | 0.41 |
PCT D2 | 1.5 (0.1-162.0) | 1.4 (0.1-64.3) | 1.6 (0.1-162.0) | 0.28 |
PCT D3 | 1.3 (0.1-345.2) | 1.5 (0.1-56.2) | 1.2 (0.1-345.2) | 0.71 |
PCT D4 | 1.2 (0.1-199.2) | 1.0 (0.1-35.3) | 1.2 (0.1-199.2) | 0.61 |
Ventilator-free days | 4.0 (0.0-112.0) | 2.0 (0.0-30.0) | 4.0 (0.0-112.0) | <0.01 |
Length of ICU stay (days) | 26.0 (4.0-204.0) | 25.0 (4.0-147.0) | 26.0 (5.0-204.0) | 0.80 |
Duration of MV (days) | 20.0 (2.0-176.0) | 20.0 (2.0-121.0) | 19.0 (2.0-176.0) | 0.42 |
30-day mortality (n (%)) | 100 (28.6) | 33 (35.5) | 67 (26.2) | 0.09 |